expanded cord blood progenitors

Expanded cord blood progenitors refer to a class of cellular therapies where hematopoietic stem and progenitor cells (HSPCs) derived from umbilical cord blood are expanded ex vivo to increase the total cell dose prior to transplantation. The specific product described in the context (dilanubicel; DVX-101) is an off-the-shelf, non-HLA-matched, cryopreserved progenitor cell product developed using a proprietary Notch-mediated expansion platform. By culturing purified CD34+ cells with the Notch ligand Delta-1, the manufacturing process generates a high dose of myeloid progenitors. When infused as an adjuvant to a conventional cord blood transplant, these cells provide a rapid, transient wave of myeloid reconstitution (neutrophils and monocytes), effectively bridging the period of profound neutropenia typically associated with cord blood grafts. This approach aims to reduce the time to engraftment and the risk of early transplant-related mortality (TRM) and infections in patients with high-risk hematologic malignancies.

Other names

dilanubicelexpanded progenitor cell productEPCNotch-expanded cord blood progenitorsoff-the-shelf expanded CB product